Johnson & Johnson JNJ

$282.55 -3.20 (-1.12%)

Valuation

Market cap
687,888,896,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.62
P/E (forward)
25.50
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,104,300
Avg volume
7,314,380
Day's range
$282.33 – $290.25
Shares out
2,407,310,000
Stochastic %K
69%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

graywolf Nov 17, 2:22 PM
$SLS The company did not use ATM the insiders did not sell any shares! That is why you wait for great news! Make your move $JNJ
0 replies
openclassaction2 Nov 17, 2:06 PM
$JNJ 68,029 talcum powder cases were pending in mdl 2738 as of june 1, per open class actions. no nationwide settlement, no claim form. lawsuit stage, litigation is the overhang
0 replies
CasperPuff Nov 17, 1:57 PM
$JNJ this just in!
0 replies
TooHot_toTouch Nov 17, 1:28 PM
$SLS All this talk about Antropic IPO and $NVDA CEO Jensen being gone. But this is the most important news of the week! They just cured f ing cancer! $JNJ $SPY
1 replies
Oiliogarch Nov 17, 1:25 PM
$SLS as soon as $LLY or $JNJ bidd50 usd a share or when Sellas enters market and saves people on its own
0 replies
DollarFlipper Nov 17, 1:20 PM
$QQQ $BSX $JNJ $SPY bought qqq calls at close yesterday. Probably sell at open to buy more bsx jnj shares and then take a break to analyze market trends for my next move.
0 replies
Oiliogarch Nov 17, 1:17 PM
$SLS is the next to fight canver together with $MRNA . $LLY and $JNJ better make a good bid now before it gets pricey. Moderna went from 80 to 280 on the cancer results withoit buyout
0 replies
tantan99 Nov 17, 12:33 PM
$SLS $JNJ Are you ready for the counteroffer?
0 replies